Bristol-Myers is buying biotech firm Medarex for $2.1 billion to bolster the U.S. drugmaker's drug pipeline and capability to produce biologic drugs.
twocents@thestreet.com (Adam Feuerstein ), The Street
Wed, 07/22/2009 - 9:00pm